ARDX — Expiration of Patent US8541448 for IBSRELA
Aug 1, 2033, 12:00:00 AM UTC
Summary
The patent US8541448 for Ardelyx Inc's drug IBSRELA is set to expire on August 1, 2033. IBSRELA is designed to treat disorders associated with fluid retention or salt overload, including conditions such as heart failure, chronic kidney disease, and gastrointestinal tract disorders. The expiration of this patent may allow for the introduction of generic alternatives, which could impact Ardelyx's market share and revenue in the related therapeutic areas.
Company
ARDELYX INC (ARDX)NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
www.ardelyx.comSimilar Events
Expiration of US Patent 9408840 for IBSRELA
The expiration of US Patent 9408840 for IBSRELA, a product of Ardelyx Inc, is scheduled for December 30, 2029. This patent covers compounds used for treating conditions such as irritable bowel syndrome and chronic kidney disease. The expiration of this patent may open the market for generic versions of the drug, potentially impacting Ardelyx's revenue and market position in the gastrointestinal treatment sector.
Patent ExpirationPatent US9006281 Expiration for IBSRELA
The patent US9006281 related to Ardelyx Inc's product IBSRELA is set to expire on May 2, 2030. IBSRELA is designed for the treatment of irritable bowel syndrome as well as chronic kidney disease and end-stage renal disease. This expiration may lead to increased competition and potential revenue impacts for Ardelyx, impacting market dynamics for its product offerings.
patent expirationExpiration of Patent USRE47739 for IBRANCE
Patent USRE47739 for IBRANCE, a treatment for cell proliferative disorders, is set to expire on March 5, 2027. The patent covers substituted 2-aminopyridines which are potent inhibitors of cyclin-dependent kinases 4 (cdk4). The expiration of this patent may allow for generic competition in the market, impacting sales for Pfizer Inc.
Patent ExpirationExpiration of Patent US8754096 for UBRELVY
The patent US8754096 for UBRELVY, assigned to Merck Sharp and Dohme LLC and AbbVie Inc, is set to expire on July 19, 2032. UBRELVY is a medication that features piperidinone carboxamide azaindane derivatives as its active compounds, which act as antagonists of CGRP receptors, playing a significant role in the treatment or prevention of migraine and related diseases. The expiration of this patent may lead to increased competition in the migraine treatment market, potentially affecting the financial performance of the involved companies.
Patent ExpirationExpiration of Patent US9834539 for REZLIDHIA
The U.S. Patent US9834539, associated with REZLIDHIA, a treatment for cell-proliferation disorders and cancers, is set to expire on September 18, 2035. This patent, held by Forma Therapeutics Inc and Rigel Pharmaceuticals Inc, covers inhibitors of mutant isocitrate dehydrogenase proteins, which play a crucial role in the pathology of various cancers. The expiration is likely to allow for increased generic competition in the market, potentially impacting future revenues for Forma Therapeutics and Rigel Pharmaceuticals.
Patent ExpirationExpiration of Patent US11925709 for UBRELVY
Merck Sharp and Dohme LLC and AbbVie Inc.'s patent US11925709 for UBRELVY, a medication designed to aid in the rapid disintegration of a drug compound within a polymer matrix, is set to expire on January 30, 2035. This expiration could have significant commercial implications, potentially allowing generic versions of the drug to enter the market, thereby affecting the revenue streams of both companies involved. The patent underscores the formulation's effectiveness in managing the active pharmaceutical ingredient (API).
Patent ExpirationExpiration of Patent US8479730 for SEEBRI
The expiration of Patent US8479730, assigned to Novartis AG and NOVARTIS PHARMACEUTICALS CORP, is set for October 11, 2028. This patent covers an inhaler device designed for powdered medicaments, illustrating the technological innovation behind SEEBRI, a drug utilized for respiratory conditions. The device enables the inhalation of medicament capsules through a unique design involving air passages and a mouthpiece structure that facilitates effective delivery. The expiration could allow for increased competition in the market, impacting Novartis' revenue from SEEBRI.
Patent ExpirationExpiration of Patent US8722735 for IZBA
Patent US8722735 for the ophthalmic product IZBA, which includes a therapeutic agent such as travoprost combined with a surfactant like castor oil to enhance bioavailability, is set to expire on October 10, 2029. The patent is held by Novartis AG and NOVARTIS PHARMACEUTICALS CORP. The expiration may open the market for generic versions of IZBA, potentially impacting Novartis' revenues from this product.
Patent ExpirationExpiration of Patent US11986481 for product REZDIFFRA
The patent US11986481 for the product REZDIFFRA, assigned to Hoffmann La Roche Inc, is set to expire on September 17, 2033. REZDIFFRA is associated with the synthesis of pyridazinone compounds that function as thyroid hormone analogs, beneficial for large-scale preparation with high purity. The patent encompasses methods that enhance the yield of these compounds, which are crucial for treating thyroid hormone resistance in patients with TRβ mutations. The expiration may impact Madrigal Pharmaceuticals Inc as they are involved in this domain, potentially influencing market competition and accessibility to generic versions of REZDIFFRA.
Patent Expiration